Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 130-162-Neuroendocrinology
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-155
Ilkay Cakir*1, Fahri Bayram2, Gulden Baskol2, Zuleyha Karaca2, Gulsah Elbuken3, Meral Mert4 and Ahmet Candan Durak3
1Numune Hospital,SIVAS, SİVAS, Turkey, 2Faculty of Medicine, Erciyes University, Kayseri, Turkey, 3Erciyes University, Kayseri, Turkey, 4Kayseri Education and Research Hospital, Kayseri, Turkey
OBJECTIVE: Although prolactin is considered to be a multipotent hormone associated not only with gonadal disfunction but also with metabolic conditions; results of clinical studies are conflicting. We aimed to investigate the effects of hyperprolactinemia on insulin resistance, lipid abnormalities, and low-grade inflammation.

PATİENTS AND METHODS: Thirty- four patients  (24 women and 10 men) with prolactinoma, and 20 age, gender and BMI matched healthy volunteers were enrolled to the study. The patients with mass effects were underwent to transsphenoidal adenomectomy, while others received medical therapy with a dopamine agonistic agent-cabergoline. Antropometric data were recorded at baseline and after at least 3 months following normalisation of serum prolactin levels. Also blood samples were obtained for the measurement of serum prolactin, thyroid stymulating hormone, glucose, insulin, adiponectin, high sensitivity C-reactive protein (hs-CRP), tumour necrosis factor(TNF)-α, interleukin (IL)-6, and lipids. Homeostasis model assessment (HOMA-IR) is used to determine insulin resistance.

RESULTS: Body mass index( BMI), waist circumference, waist/hip ratio, body fat percent and levels of total cholesterol showed significant reductions in patient group after treatment compared to baseline values. Scores of HOMA-IR of patients were higher than controls before treatment and decreased following normalisation of PRL levels but the changes didn’t reach to statistical significancy. Interleukin-6, and hs-CRP levels decreased significantly after treatment in obese patients.

CONCLUSION: The alterations observed in  hyperprolactinemic subjects may be associated with weight gain, hypogonadism or dysregulation of dopaminergic system, because no corelation was found between PRL levels and evaluated parameters. Longer durations of follow-up and direct comparison of surgical and medical treatments of hyperprolactinemia are required.

Nothing to Disclose: IC, FB, GB, ZK, GE, MM, ACD

*Please take note of The Endocrine Society's News Embargo Policy at